John Marshall, PhD, FRCPath, FMedSci, concurrently Medical Advisory Board member at Avellino Labs and Frost Professor of Ophthalmology at UCL Institute of Ophthalmology and Moorfields Eye Hospital, commented, "At Avellino Labs we are excited to be able to offer the first genetic predictor of relative risk of keratoconus in Asian eyes, which often hits in the prime of life and progressively impairs vision over time. Most importantly, the Avellino DNA Test represents a sea change detecting keratoconus early in order to inform surgeons performing laser vision correction and to improve keratoconus patient care."
Avellino Labs continues to invest in research and development aimed at expanding its molecular diagnostic platform. The company's aim is to provide a comprehensive diagnostic assay to determine a definitive risk factor for keratoconus for patients on a global level.
About Avellino Labs
Avellino Labs is the global leader in gene therapy and molecular diagnostics pioneering personalized medicine for eye care. Avellino's Universal Test is the world's first DNA test adopted to confirm LASIK candidates are free of genetic indicators associated with poor outcomes. Avellino Labs is also pioneering CRISPR gene editing to manage and potentially cure corneal dystrophies and other inherited eye diseases. Avellino Labs is headquartered in Silicon Valley, California with operations in Korea, Japan, China and the UK.
Avellino Labs was named a 2015 Technology Pioneer by the World Economic Forum based on its potential to impact global health.
To learn more please visit http://www.avellinolabs.com/us/ or follow us on Twitter @Avellinolab_USA
Director of Marketing Communications
972.517.1784 / 214.356.4427 (mobile)
Logo - http://photos.prnewswire.com/prnh/20130514/SF12152LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/avellino-labs-to-introduce-keratoconus-screening-test-in-early-2017-300361069.html
SOURCE Avellino Labs